Literature DB >> 17157495

Imaging myocardial metabolism.

Keiichiro Yoshinaga1, Nagara Tamaki.   

Abstract

The prevalence of coronary artery disease and heart failure is increasing in modern industrialized countries, fueling the search for novel therapies. Because metabolism and function in the heart are inextricably linked, energy substrate metabolism has provided a potential target for novel therapies and the development of technologies to image myocardial metabolism has been crucial in establishing new therapeutic approaches. Nuclear imaging probes have been used to successfully evaluate aerobic fatty acid metabolism, anaerobic glucose metabolism, and oxidative metabolism and can be used for the accurate, sensitive, and physiological evaluation of therapeutic effects. More recently, with the advent of stem-cell technologies, imaging approaches have been employed to track the fate of stem cells and to monitor the success of these treatments. In the future, our ability to image myocardial metabolism is likely to assist the development of other new therapies to improve the function of the failing heart.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17157495     DOI: 10.1016/j.copbio.2006.11.003

Source DB:  PubMed          Journal:  Curr Opin Biotechnol        ISSN: 0958-1669            Impact factor:   9.740


  11 in total

1.  Synthesis and evaluation of 15-(4-(2-[¹⁸F]Fluoroethoxy)phenyl)pentadecanoic acid: a potential PET tracer for studying myocardial fatty acid metabolism.

Authors:  Zhude Tu; Shihong Li; Terry L Sharp; Pilar Herrero; Carmen S Dence; Robert J Gropler; Robert H Mach
Journal:  Bioconjug Chem       Date:  2010-11-11       Impact factor: 4.774

Review 2.  Recommendations for 18F-fluorodeoxyglucose positron emission tomography imaging for diagnosis of cardiac sarcoidosis-2018 update: Japanese Society of Nuclear Cardiology recommendations.

Authors:  Shinichiro Kumita; Keiichiro Yoshinaga; Masao Miyagawa; Mitsuru Momose; Keisuke Kiso; Tokuo Kasai; Masanao Naya
Journal:  J Nucl Cardiol       Date:  2019-08       Impact factor: 5.952

3.  Optimizing myocardial metabolism for fluorine-18 fluorodeoxyglucose positron emission tomography imaging of cardiac inflammation.

Authors:  Efstathia Andrikopoulou; Pradeep Bhambhvani
Journal:  J Nucl Cardiol       Date:  2017-04-21       Impact factor: 5.952

4.  Challenges of cardiac inflammation imaging with F-18 FDG positron emission tomography.

Authors:  Pradeep Bhambhvani
Journal:  J Nucl Cardiol       Date:  2016-05-04       Impact factor: 5.952

Review 5.  ¹⁸F-Fluoro-2-deoxyglucose positron emission tomography in cardiac sarcoidosis.

Authors:  Hiroshi Ohira; Ichizo Tsujino; Keiichiro Yoshinaga
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-05-11       Impact factor: 9.236

Review 6.  Ischaemic memory imaging using metabolic radiopharmaceuticals: overview of clinical settings and ongoing investigations.

Authors:  Keiichiro Yoshinaga; Masanao Naya; Tohru Shiga; Eriko Suzuki; Nagara Tamaki
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-11-12       Impact factor: 9.236

7.  Real-time noninvasive imaging of fatty acid uptake in vivo.

Authors:  Amy H Henkin; Allison S Cohen; Elena A Dubikovskaya; Hyo Min Park; Gennady F Nikitin; Mathieu G Auzias; Melissa Kazantzis; Carolyn R Bertozzi; Andreas Stahl
Journal:  ACS Chem Biol       Date:  2012-09-06       Impact factor: 5.100

Review 8.  Assessment of cardiac sarcoidosis with advanced imaging modalities.

Authors:  Makoto Orii; Toshio Imanishi; Takashi Akasaka
Journal:  Biomed Res Int       Date:  2014-08-28       Impact factor: 3.411

9.  Evaluation of myocardial glucose metabolism in hypertrophic cardiomyopathy using 18F-fluorodeoxyglucose positron emission tomography.

Authors:  Rie Aoyama; Hitoshi Takano; Yasuhiro Kobayashi; Mitsunobu Kitamura; Kuniya Asai; Yasuo Amano; Shin-Ichiro Kumita; Wataru Shimizu
Journal:  PLoS One       Date:  2017-11-27       Impact factor: 3.240

10.  The effects of 18-h fasting with low-carbohydrate diet preparation on suppressed physiological myocardial (18)F-fluorodeoxyglucose (FDG) uptake and possible minimal effects of unfractionated heparin use in patients with suspected cardiac involvement sarcoidosis.

Authors:  Osamu Manabe; Keiichiro Yoshinaga; Hiroshi Ohira; Atsuro Masuda; Takahiro Sato; Ichizo Tsujino; Asuka Yamada; Noriko Oyama-Manabe; Kenji Hirata; Masaharu Nishimura; Nagara Tamaki
Journal:  J Nucl Cardiol       Date:  2015-08-05       Impact factor: 5.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.